Ribavirin News and Research

RSS

Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.

Drug repurposing study finds lonafarnib effective against RSV

A study in Nature Communications identifies lonafarnib from the ReFRAME drug-repurposing library as a potent inhibitor of the RSV fusion protein, showing promise in reducing RSV infection in vitro and in vivo.

11 Feb 2024

Study provides valuable insights into the evolutionary dynamics of hepatitis E virus

A combination therapy with multiple drugs is more effective than just one active compound. To begin with, at least.

23 Jan 2024

RSV in seniors: Less common than COVID-19, but hits harder, CDC study reveals

In a recent CDC's MMWR study, researchers found that while respiratory syncytial virus (RSV) infections are less common than COVID-19 and influenza in Americans aged 60+ years, they result in much more severe clinical outcomes. This insight supports the CDC's recommendation for RSV vaccination in older adults, emphasizing its potential in preventing severe respiratory disease.

10 Oct 2023

The potential benefits of ribavirin and pleconaril treatment on type 1 diabetes

Researchers investigate whether ribavirin and pleconaril could stimulate endogenous insulin production among individuals with incident type 1 diabetes.

8 Oct 2023

Antiviral treatment emerges as a potential game-changer in curbing type 1 diabetes progression

New research from the University of Oslo reveals antiviral drugs could help preserve insulin production in children newly diagnosed with type 1 diabetes, potentially slowing down or even preventing the disease. The study, building on earlier findings linking enterovirus to type 1 diabetes, showed that antiviral treatment led to maintained insulin production, proposing a new therapeutic avenue to treat and mitigate the progression of type 1 diabetes.

3 Oct 2023

The immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species

Researchers characterized the immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species.

19 Jul 2023

Single mutation of the hepatitis E virus stands in the way of sofosbuvir drug's effectiveness

A single mutation stands in the way of a drug's effectiveness. Understanding it helps find new therapeutic approaches.

21 Jun 2023

Battle against RSV: Computational design paves way for new polyvalent vaccine

Research focuses on the design of a multi-epitope polyvalent vaccine against Human Respiratory Syncytial Virus (RSV), a leading cause of lower respiratory tract infections. The study utilizes computational methods and immunoinformatics tools to predict potential vaccine candidates and their interactions with Toll-like receptors (TLRs).

19 Jun 2023

Urgent call for improved diagnostics, treatments, and vaccines against deadly Hantavirus

Scientists discuss hantavirus infections, which are a type of viral hemorrhagic fever that can be transmitted to humans through exposure to infected rodents in endemic areas.

30 Apr 2023

A review of emerging pediatric respiratory viruses

Respiratory viruses continue to be a leading cause of childhood morbidity and mortality.

26 Oct 2022

Inhalation therapeutics against COVID-19

A recent study published in the Pulmonary Pharmacology & Therapeutics journal described different inhalation therapeutic agents for treating respiratory viral infections like coronavirus disease 2019 (COVID-19).

17 Oct 2022

Are men or women impacted more by adverse reactions to prescription drug treatments?

Recently, researchers presented an overview of sex-based differences in adverse drug reactions (ADRs) based on epidemiology, technique, and underlying mechanism data.

11 Oct 2022

RNA-dependent RNA polymerase inhibitors in COVID-19 therapy

A new paper reviews current knowledge of RdRp inhibitors that could be developed further to provide broadly effective antivirals against SARS-CoV-2 in particular and CoVs in general.

10 Oct 2022

Does Langya virus pose a spillover threat?

Researchers assess the potential impact of the Langya virus, its current risk, and what measures might help to contain this virus.

30 Aug 2022

Study provides insights into understanding the biology of circulating Hepatitis E variants

Over three million people are infected with the hepatitis E virus every year. So far, no effective treatment is available. An international team has investigated which factors are important for the virus in the course of its replication cycle and how it manages to maintain the infection.

17 Aug 2022

Ribavirin News and Research

Further Reading

Drug repurposing study finds lonafarnib effective against RSV

Study provides valuable insights into the evolutionary dynamics of hepatitis E virus

RSV in seniors: Less common than COVID-19, but hits harder, CDC study reveals

The potential benefits of ribavirin and pleconaril treatment on type 1 diabetes

Antiviral treatment emerges as a potential game-changer in curbing type 1 diabetes progression

The immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species

Single mutation of the hepatitis E virus stands in the way of sofosbuvir drug's effectiveness

Battle against RSV: Computational design paves way for new polyvalent vaccine

Urgent call for improved diagnostics, treatments, and vaccines against deadly Hantavirus

A review of emerging pediatric respiratory viruses

Inhalation therapeutics against COVID-19

Are men or women impacted more by adverse reactions to prescription drug treatments?

RNA-dependent RNA polymerase inhibitors in COVID-19 therapy

Does Langya virus pose a spillover threat?

Study provides insights into understanding the biology of circulating Hepatitis E variants

Scientists introduce SARS-CoV-2 phenotype screening for identifying novel antiviral drugs

Nitazoxanide drug found to be a potent inhibitor of several human coronaviruses

What are the biological features, prevention and control strategies against monkeypox?

Chemically modified rocaglates have a stronger effect against viral replication

Probenecid shows activity against respiratory syncytial virus

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News